Literature DB >> 54235

E and EAC rosetting lymphocytes in patients with carcinoma of bronchus. II. A sequential study of thirty patients: effect of BCG.

H M Anthony, J A Kirk, K E Madsen, M K Mason, G H Templeman.   

Abstract

T and B lymphocytes have been estimated in thirty patients with carcinoma of bronchus at monthly intervals. The patients have been treated by surgery, radiotherapy or no conventional antineoplastic therapy, with or without monthly intradermal BCG. Significant increase in T-lymphocyte percentages occurred in three out of six patients treated by BCG and no conventional therapy, and similar increases were observed in other BCG-treated patients. Patterns emerged suggesting that the T-lymphocyte percentage may be depressed, directly or indirectly, by tumour and recover after surgery or palliative radiotherapy; that high T-lymphocyte levels may accompany reactive lymphocytosis to tumour and that T-lymphocyte collapse was associated with, and appeared to precede terminal clinical deterioration in many patients.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 54235      PMCID: PMC1538175     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  10 in total

1.  E and EAC rosetting lymphocytes in patients with carcinoma of bronchus I. Some parameters of the test and of its prognostic significance.

Authors:  H M Anthony; J A Kirk; K E Madsen; M K Mason; G H Templeman
Journal:  Clin Exp Immunol       Date:  1975-04       Impact factor: 4.330

2.  The prognostic significance of DHS skin tests in patients with carcinoma of bronchus.

Authors:  H M Anthony; G H Templeman; K E Madsen; M K Mason
Journal:  Cancer       Date:  1974-12       Impact factor: 6.860

3.  Lymphopenia and change in distribution of human B and T lymphocytes in peripheral blood induced by irradiation for mammary carcinoma.

Authors:  J Stjernswärd; M Jondal; F Vánky; H Wigzell; R Sealy
Journal:  Lancet       Date:  1972-06-24       Impact factor: 79.321

4.  Correlation of preoperative lymphocyte reactivity with the clinical course of cancer patients.

Authors:  P B Chretien; W L Crowder; H R Gertner; W F Sample; W J Catalona
Journal:  Surg Gynecol Obstet       Date:  1973-03

5.  Immunological changes after radiotherapy for mammary carcinoma.

Authors:  J Stjernswärd
Journal:  Ann Inst Pasteur (Paris)       Date:  1972-04

6.  Immunologic alterations in bronchogenic cancer. Sequential study.

Authors:  M J Krant; G Manskopf; C S Brandrup; M A Madoff
Journal:  Cancer       Date:  1968-04       Impact factor: 6.860

7.  Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils.

Authors:  A Riesco
Journal:  Cancer       Date:  1970-01       Impact factor: 6.860

8.  Radiation-induced lymphocyte-immune deficiency. A factor in the increased visceral metastases and decreased hormonal responsiveness of breast cancer.

Authors:  K K Meyer
Journal:  Arch Surg       Date:  1970-08

9.  Studies of peripheral blood T-and B-lymphocytes in acute infections.

Authors:  P M Niklasson; R C Williams
Journal:  Infect Immun       Date:  1974-01       Impact factor: 3.441

10.  Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells.

Authors:  M Jondal; G Holm; H Wigzell
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

  10 in total
  13 in total

1.  E and EAC rosetting lymphocytes in patients with carcinoma of bronchus I. Some parameters of the test and of its prognostic significance.

Authors:  H M Anthony; J A Kirk; K E Madsen; M K Mason; G H Templeman
Journal:  Clin Exp Immunol       Date:  1975-04       Impact factor: 4.330

2.  Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immune-reactivity in relation to immunostimulation (preliminary results in a controlled trial).

Authors:  H M Jansen; T H The; G C de Gast; M T Esselink; A M van der Wal; N G Orie
Journal:  Thorax       Date:  1978-08       Impact factor: 9.139

3.  The relationship of defective cell-mediated immunity to visceral disease in systemic sclerosis.

Authors:  P Hughes; S Holt; N R Rowell; I D Allonby; K Janis; J K Dodd
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

Review 4.  Serial immune function testing to predict clinical disease relapse in patients with solid tumors.

Authors:  D P Braun; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

5.  Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.

Authors:  N Thatcher; R Swindell; D Crowther
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

6.  [Investigations of unspecific immune reactivity in patients with head and neck carcinoma (author's transl)].

Authors:  J Bier; U Nicklisch
Journal:  Arch Otorhinolaryngol       Date:  1981

7.  Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours.

Authors:  W H Brooks; T L Roszman; M S Mahaley; R E Woosley
Journal:  Clin Exp Immunol       Date:  1977-07       Impact factor: 4.330

8.  Serial immune testing in surgically resected lung cancer patients.

Authors:  D P Braun; S Nisius; A Hollinshead; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  Immune reactivity in cattle with ocular squamous cell carcinoma after intralesional BCG immunotherapy.

Authors:  W R Klein; P A Steerenberg; F Poelma; E vd Wiel; V P Rutten; W Misdorp; W H de Jong; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

10.  Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance.

Authors:  H M Anthony; C J Schorah
Journal:  Br J Cancer       Date:  1982-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.